Plenty of people take CBD products to ease pain and help them cope with neurodegenerative problems such as epilepsy and multiple sclerosis (MS).
The problem is that cannabidiol (CBD), the non-psychoactive compound found in the cannabis plant, is poorly absorbed and its effectiveness is lessened.
Scientists at the University of South Australia think they may have solved the problem by creating a phospholipid complex—a class of lipids (fats) that contain phosphorus—that increase the solubility of cannabidiol by up to six times and improve its absorption in the gastrointestinal (GI) tract.
One of the researchers, Thabata Muta, says: “Improved bioavailability means that lower doses can achieve the same therapeutic effect, potentially reducing side effects and making treatment more cost effective.”
The research team believes that this innovation could be applied beyond CBD, providing a blueprint for enhancing the absorption of other water-soluble drugs. They are now exploring commercial opportunities and clinical trials to validate their new formulation.
Their timing is good: the global CBD market is projected to grow from $7.59 bn in 2023 to $202.45 bn by 2032.
What do you think? Start a conversation over on the... WDDTY Community
International Journal of Molecular Sciences, 2025; 26 (6): 2647; doi: 10.3390/ijms26062647
Great news! Discounts are available based on your cart total. Check the details below: